Caitlin Averill
Primary Care · Reisterstown, MDNPI 1003200791
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,160, more than ten times the $15 reported in 2022.
Across 131 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$425
- AbbVie$372
- AstraZeneca$281
- Pfizer$264
- Lilly USA, LLC$155
- Amgen$151
- plus $848 from 16 others
What the payments were for
- Food & beverage$2,495100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $425 |
| AbbVie | 17 | $372 |
| AstraZeneca | 14 | $281 |
| Pfizer | 13 | $264 |
| Lilly USA, LLC | 9 | $155 |
| Amgen | 9 | $151 |
| Exact Sciences | 5 | $131 |
| Shield Therapeutics Inc | 4 | $118 |
| Astellas Pharma US Inc | 6 | $98 |
| Bayer | 3 | $73 |
| Boehringer Ingelheim | 4 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Dexcom, Inc. | 3 | $51 |
| GSK | 3 | $50 |
| UCB, Inc. | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Aerin Medical Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Abbott | 1 | $14 |
How this compares
$2,495 in reported general payments places this provider in the 85th percentile of 191 primary care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 42 | $87,582 |
| OzempicSemaglutide | 65 | $65,359 |
| JardianceEmpagliflozin | 37 | $54,651 |
| XareltoRivaroxaban | 22 | $21,252 |
| MounjaroTirzepatide | 19 | $18,570 |
| MyrbetriqMirabegron | 11 | $5,982 |
| PaxlovidNirmatrelvir/Ritonavir | 14 | $2,809 |
| Atorvastatin Calcium | 196 | $2,741 |
| Rosuvastatin Calcium | 73 | $1,505 |
| Memantine Hcl | 11 | $1,318 |
| Metoprolol Succinate | 83 | $1,187 |
| Losartan Potassium | 80 | $1,174 |
| Gabapentin | 66 | $981 |
| Ezetimibe | 17 | $962 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $155 | $106,15261 claims |
| Novo NordiskOzempic | $425 | $65,35965 claims |
| Boehringer IngelheimJardiance | $69 | $54,65137 claims |
| Astellas Pharma US IncMyrbetriq | $98 | $5,98211 claims |
| PfizerPaxlovid | $264 | $2,80914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 191 primary care providers in Maryland.
Other primary care in Reisterstown
- Ashley SalamoneBaltimore$13K
- Ololade IkuomolaBaltimore$10K
- Patricia GoodmanUppr Marlboro$8K
- Jody LeonardAnnapolis$7K
- Yury MalachevskyBaltimore$7K
- Kyleen DavisChevy Chase$6K
- Laura Ferguson-WeigmanBel Air$5K
- Roza LissGaithersburg$5K
- Anita Tuli-KendallGaithersburg$5K
- Hannah WhiteheadEssex$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.